Firebrick Pharma Limited (ASX: FRE)
Australia
· Delayed Price · Currency is AUD 0.0560
+0.0020 (3.70%)
Dec 20, 2024, 3:45 PM AEST
Firebrick Pharma Company Description
Firebrick Pharma Limited engages in the development and commercializing of novel formulations for the uses of povidone iodine in Australia.
The company offers broad-spectrum antimicrobial nasal spray for the treatment of common cold under the Nasodine name.
It also operates in the United states and Singapore. Firebrick Pharma Limited was incorporated in 2012 and is based in Melbourne, Australia.
Firebrick Pharma Limited
| Country | Australia |
| Founded | 2012 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| CEO | Peter Molloy |
Contact Details
Address: 440 Collins Street Melbourne, 3000 Australia | |
| Phone | 1300 301 874 |
| Website | firebrickpharma.com |
Stock Details
| Ticker Symbol | FRE |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000197352 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Peter Laurence Molloy BSc, FAICD, MBA | Founder, Executive Chairman and Chief Executive Officer |
| Dr. Stephen Francis Goodall MASc, MBA | Founder, Chief Operating Officer and Executive Director |
| Kavi Bekarma B.Sc., C.A. | Chief Financial Officer |
| Dr. Simon Tucker | Chief Scientific Officer |
| Prof. Peter Friedland | Chief Medical Officer |
| Dr. Monique Baldwin | Head of Regulatory Affairs |
| Stephen Buckley | Company Secretary |